Market Closed -
Other stock markets
|
Pre-market 07:18:18 am | |||
168.6 USD | +1.89% | 168.6 | +0.04% |
12:00pm | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
Jun. 06 | AbbVie Says Mid-Stage Study of Mirvetuximab Soravtansine to Treat Ovarian Cancer Meets Primary Endpoint | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.78% | 298B | |
+43.64% | 754B | |
+40.09% | 630B | |
-6.58% | 352B | |
+19.72% | 331B | |
+11.99% | 217B | |
-1.10% | 216B | |
+0.03% | 163B | |
+6.13% | 164B | |
+0.13% | 124B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating